Given the high prevalence and adverse prognostic significance of iron deficiency and anemia in people with HF23–26, better clarification of possible biological links between changes in iron status and the beneficial clinical effects of SGLT2 inhibitors is desirable. This evidence concerns the gene SLC5A2 and anemia (phenotype).